Aliada Therapeutics

Aliada Therapeutics is a biotechnology startup that aims to revolutionize the treatment of central nervous system (CNS) diseases by overcoming the challenge of crossing the blood-brain barrier. With the slogan "Beyond boundaries: Crossing the blood-brain barrier to create the next generation of central nervous system therapies," Aliada is focused on developing novel therapies for CNS diseases that are traditionally hard to treat due to the complexity of the brain's immune environment. The company has devised a highly versatile platform that has shown promising results in non-human primates, demonstrating proof of concept. This platform encompasses a wide range of modalities, including monoclonal antibodies, enzymes, oligonucleotides, peptides, and other proteins, with a customizable delivery technology tailored for CNS tissue and target localization. Aliada's unique approach involves binding two distinct transport targets on the blood-brain barrier, enabling effective delivery of therapeutic compounds to the CNS. In addition to its platform, Aliada is leveraging its innovative technology to develop specific CNS target antibody binders and is progressing these programs through preclinical evaluation. Established in 2021, Aliada has garnered significant attention in the biotechnology, healthcare, and life sciences industries. The company recently secured a substantial $32.00M investment through a Venture Round at 30 December 2022, indicative of the confidence and interest from potential investors in its groundbreaking approach to CNS drug development.